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CRIMES AND OFFENSES 
Controlled Substances: Amend Chapter 13 of Title 16 and Chapter 
4 of Title 26 of the Official Code of Georgia Annotated, Relating to 
Controlled Substances and Pharmacists and Pharmacies, 
Respectively, so as to Implement Various Measures Relating to the 
Regulation and Security of Prescribing and Dispensing Controlled 
Substances; Provide for the Establishment of a Program to Monitor 
the Prescribing and Dispensing of Schedule II, III, IV, and V 
Controlled Substances; Provide for Definitions; Require Dispensers 
to Submit Certain Information Regarding the Dispensing of Such 
Controlled Substances; Provide for the Confidentiality of Submitted 
Information Except under Certain Circumstances; Provide for the 
Establishment of an Electronic Database Review Advisory 
Committee; Provide for Its Membership, Duties, and Organization; 
Provide for the Establishment of Rules and Regulations; Provide 
for Limited Liability; Provide for Penalties; Require that Hard 
Copy Prescriptions for Schedule II Controlled Substances Be on 
Security Paper; Redefine the Term “Security Paper” and Provide 
for Approval of Such Paper Prior to Sale by the State Board of 
Pharmacy; Provide for Exceptions; Provide for Rules and 
Regulations; Require Identification from Persons Picking Up 
Certain Prescriptions; Provide for Related Matters; Provide for an 
Effective Date; Repeal Conflicting Laws; and for Other Purposes. 
CODE SECTIONS: O.C.G.A. §§ 16-13-21 (amended), -57 
(new), -58 (new), -59 (new), -60 (new), 
-61 (new), -62 (new), -63 (new), -64 
(new), -65 (new); 26-4-5 (amended); 
26-4-80.1 (new); 26-4-80.2 (new) 
BILL NUMBER: SB 36 
ACT NUMBER:  229 
GEORGIA LAWS: 2011 Ga. Laws 659  
SUMMARY: The Act authorizes the Georgia Drugs 
and Narcotics Agency to establish and 
maintain a program to record and 
monitor the prescription and dispensing 
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of Schedule II, III, IV, and V controlled 
substances. It provides for 
confidentiality of the submitted 
information and establishes penalties 
for the breach of these provisions. It 
also provides for the establishment of 
an Electronic Database Review 
Advisory Committee and for its 
membership. The Act requires that 
Schedule II written prescriptions be on 
security paper. 
EFFECTIVE DATE: July 1, 2011 
History 
In recent years, Georgia has seen a dramatic increase in 
prescription drug addiction.1 Bolstering this problem are “pill mills;” 
comprised of pharmacies, doctors, or clinics that prescribe or 
dispense painkillers inappropriately or for non-medical purposes, to 
addicts and drug dealers, sometimes without even examining the 
patient.2 These facilities prey on addicts, often accepting only cash 
payments, refusing to take appointments, and failing to maintain 
medical records.3 Georgia became a target for these rogue doctors, 
pharmacists, addicts, and drug dealers because it was one of only 
four states without legislation establishing a prescription drug 
monitoring program.4 As a result, Georgia provided a safe harbor for 
                                                                                                                                         
 1. Senator Buddy Carter, the bill’s sponsor, described the situation in Georgia as an “epidemic.” 
Interview with Sen. Buddy Carter (R-1st) (Mar. 29, 2011) [hereinafter Carter Interview] (on file with the 
Georgia State University Law Review). “There were 584 prescription drug overdose deaths in Georgia 
in 2009, according to records from the GBI Medical Examiner’s Office. By comparison, there were 86 
deaths from illegal drug overdoses.” April Hunt & Andria Simmons, Trailing an Elusive Killer, 
ATLANTA J.-CONST., May 7, 2011, at B2, available at http://www.ajc.com/news/georgia-politics-
elections/trailing-an-elusive-killer-938655.html. 
 2. Greg Bluestein, Feds in Ga. to Ramp up “Pill Mill” Investigations, ASSOCIATED PRESS, Feb. 28, 
2011, available at http://abcnews.go.com/Business/wireStory?id=13020612&page=1; Pia Malbran, 
What’s a Pill Mill?, CBS NEWS, May 31, 2007, http://www.cbsnews.com/8301-501263_162-2872835-
501263.html.  
 3. Bluestein, supra note 2. 
 4. As of spring 2011 Georgia, Maryland, Missouri, and New Hampshire all had prescription 
monitoring program legislation pending. Status of Prescription Drug Monitoring Programs (map), The 
Alliance of States with Prescription Monitoring Programs, 
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these activities since each bordering state had enacted prescription 
monitoring program legislation.5 This failure to pass legislation was 
not due to a lack of trying; during the years preceding the passage of 
Senate Bill (SB) 36, various forms of prescription monitoring 
legislation were introduced in Georgia, but none were successful.6 
Much of the opposition to these proposals arose out of concern for 
patient privacy and funding.7 
Because the majority of states have established prescription 
monitoring databases, Georgia had many models upon which to base 
its legislation. Many states include prescription monitoring for all 
Schedule II, III, IV, and V controlled substances, while some have 
limited the database to only Schedule II, III, or IV drugs.8 At a 
minimum, all prescription monitoring programs include Schedule II 
drugs and some have included specific substances rather than an 
                                                                                                                                         
http://www.pmpalliance.org/pdf/pmpstatusmap2011.pdf (last visited June 12, 2011) [hereinafter Map of 
States with Prescription Monitoring Programs]. Eleven states plus Guam have enacted legislation, but 
their databases are not yet operational. Id. Thirty-five states have operational prescription drug 
monitoring programs. Id. 
 5. Video Recording of House Judiciary Non-Civil Committee Proceedings, Mar. 28, 2011 at 6 
min., 10 sec. (remarks by Sen. Buddy Carter (R-1st)), 
http://media.legis.ga.gov/hav/11_12/2011/committees/judiNon/judiNon032811EDITED.wmv 
[hereinafter House Committee Video]; Map of States with Prescription Monitoring Programs, supra 
note 4. 
 6. See HB 455, as introduced, 2008 Ga. Gen. Assem.; HB 614, as introduced, 2009 Ga. Gen. 
Assem.; SB 418, as introduced, 2010 Ga. Gen. Assem.; HB 184, as introduced, 2010 Ga. Gen. Assem. 
 7. Senators Reintroduce Prescription Drug Monitoring Act, PEACHPUNDIT.COM, 
http://www.peachpundit.com/2010/03/11/senators-reintroduce-prescription-drug-monitoring-act/ (Mar. 
11, 2010); Database Would Track Prescriptions, AUGUSTA CHRON., Feb. 18, 2011, at A11, available at 
http://chronicle.augusta.com/news/health/2011-02-18/database-would-track-prescriptions. 
 8. Controlled substances are divided into five schedules under 21 C.F.R. § 1308. Controlled 
Substance Schedules, http://www.deadiversion.usdoj.gov/schedules/index.html#define (last visited June 
12, 2011). A controlled substance is assigned to a schedule based on its currently accepted medical use 
and its potential for abuse or addiction. Id. As the schedule numbers increase, generally the potential for 
abuse decreases. Id. For example, Schedule II controlled substances have a high potential for abuse, but 
have medically accepted uses, whereas Schedule V controlled substances have a low potential for abuse. 
Id. Schedule I controlled substances are not included in the Prescription Monitoring Database because 
they are substances with a very high potential for abuse and no medically accepted uses. Id. 
Connecticut, Massachusetts, New York, Delaware, Alaska, Colorado, Hawaii, Idaho, Utah, Washington, 
Illinois, Indiana, Michigan, North Dakota, Ohio, Alabama, Kentucky, Louisiana, Mississippi, North 
Carolina, Oklahoma, Tennessee, and Texas monitor all Schedule II, III, IV, and V controlled substances. 
See Drug Schedules Monitored, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING PROGRAMS, 
http://www.pmpalliance.org/content/drug-schedules-monitored (last visited June 12, 2011). 
Pennsylvania’s prescription monitoring program includes only Schedule II controlled substances. Id. 
Maine, Vermont, Arizona, California, New Mexico, Nevada, Oregon, Wyoming, Iowa, Kansas, 
Minnesota, South Dakota, Florida, South Carolina, Virginia, and New Jersey collect data on all 
Schedule II, III, and IV drugs. Id. 
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entire schedule.9 Additionally, the required frequency for updating 
prescription information in the database ranges from daily to bi-
weekly to monthly.10 The individuals and entities permitted to 
request patient prescription data also varies among the states.11 Some 
states allow prescribers, pharmacists, pharmacies, law enforcement, 
licensing boards, and patients to request information, while other 
states limit these requests to law enforcement only.12 The Alliance of 
States with Prescription Monitoring Programs offers model 
legislation on its website.13 
The nationwide push to implement prescription monitoring 
programs has resulted in funding incentives provided by both the 
Federal government and private companies for states with 
programs.14 Funding is available to plan for, implement, or enhance 
an existing prescription monitoring program.15 Both the Department 
of Health and Human Services and the Department of Justice offer 
grant programs.16 However, these programs only fund state 
prescription monitoring programs that comply with certain standards, 
such as including all Schedule II, III, IV, and V controlled 
                                                                                                                                         
 9. Particularly, many states specifically include Carisoprodol, a muscle relaxant commonly known 
as SOMA, in the monitoring program. See Drug Schedules Monitored, supra note 8; J.A. Fass, 
Carisprodol Legal Status and Patterns of Abuse, 44 ANNALS OF PHARMACOTHERAPY 1962 (2010). 
Carisoprodol is not a controlled substance under federal law, but Georgia lists it as a Schedule IV 
controlled substance. Compare 21 C.F.R. § 1308.14 (2009) with GA. COMP R. & REGS. 480-34-.01 
(1996). 
 10. See PMP Data Collection Frequency, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING 
PROGRAMS, http://www.pmpalliance.org/content/pmp-data-collection-frequency (last visited June 12, 
2011). 
 11. See Who is Authorized to Request Patient Prescription Data?, ALLIANCE OF STATES WITH 
PRESCRIPTION MONITORING PROGRAMS, http://www.pmpalliance.org/content/who-authorized-request-
patient-prescription-data (last visited June 12, 2011). 
 12. Pennsylvania restricts patient prescription data requests to law enforcement only, while 
Massachusetts allows prescribers, pharmacists, pharmacies, law enforcement, and patients to request 
patient prescription information. Id. 
 13. See Prescription Monitoring Program Model Act 2010 Revision, ALLIANCE OF STATES WITH 
PRESCRIPTION MONITORING PROGRAMS, 
http://www.pmpalliance.org/pdf/PMPModelActFinal20100628.pdf (last visited June 12, 2011). 
 14. See Funding, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING PROGRAMS, 
http://www.pmpalliance.org/content/funding (last visited June 12, 2011). 
 15. Id. 
 16. See Harold Rogers Prescription Drug Monitoring Program FY 2011 Competitive Grant 
Announcement, U.S. Department of Justice, OMB No. 1121-0329, available at 
http://www.ojp.usdoj.gov/BJA/grant/11PDMPsol.pdf; National All Schedules Prescription Electronic 
Reporting Act (NASPER) of 2005 Program Grants, U.S. Department of Health and Human Services, 
available at http://www.pmpalliance.org/pdf/FY-2011-NASPER-RFA.pdf. 
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substances, sharing data with other states and the federal government, 
and ensuring patient privacy.17 These programs also do not provide 
100% of the funds necessary to plan, implement, and maintain 
prescription monitoring programs.18 
The beginning of the 2011 legislative session looked hopeful for 
prescription monitoring legislation in Georgia with bills introduced in 
both chambers.19 Even the director of the White House Office of 
National Drug Control Policy—”the White House Drug Czar”— 
expressed his support for Georgia’s efforts.20 Simultaneously, 
however, controversy arose surrounding Florida’s prescription drug 
monitoring program.21 Florida’s Governor Rick Scott is opposed to 
the database because he believes it is an invasion of privacy and puts 
taxpayers “on the hook” for a program that was not supposed to 
require state funding. 22 Despite the controversy in Florida, the 
Georgia General Assembly passed SB 36, authorizing the creation of 
a prescription monitoring database. 
Bill Tracking of SB 36 
Consideration and Passage by the Senate 
Senators Buddy Carter (R-1st), Renee Unterman (R-45th), Greg 
Goggans (R-7th), William Ligon, Jr. (R-3rd), and Charlie Bethel (R-
54th) sponsored SB 36.23 The Senate read the bill for the first time on 
                                                                                                                                         
 17. “To be eligible for a NASPER grant, state programs must track drugs that fall under schedules II, 
III, and IV of the Controlled Substances Act, and must adhere to certain privacy, reporting, and 
interoperability requirements.” Digest for HR 5710, 111th Congress, 2d Sess. (U.S. 2010), available at 
http://www.gop.gov/bill/111/2/hr5710. 
 18. Harold Rogers funding provides up to $50,000 for planning programs and up to $400,000 for 
implementation or enhancement of programs. See Harold Rogers Prescription Drug Monitoring Program 
FY 2011 Competitive Grant Announcement, supra note 16. NASPER awards $21,593–$112,398 to 
states with compliant prescription monitoring programs. See National All Schedules Prescription 
Electronic Reporting Act (NASPER) of 2005 Program Grants, supra note 16. 
 19. See HB 184, as introduced, 2011 Ga. Gen. Assem.; SB 36, as introduced, 2011 Ga. Gen. Assem. 
 20. Gil Kerlikowske, director of the White House Office of National Drug Control Policy, pointed 
out that Florida’s crackdown will force pill mills to look elsewhere, like neighboring Georgia. Carrie 
Teegardin, Database Could Flag Drug Abusers, ATLANTA J.-CONST., Feb. 18, 2011, at B1. 
 21. Janet Zink, Fight is on to Save Drug Monitoring Database, MIAMI HERALD, Mar. 14, 2011, at 
A3, available at http://www.miamiherald.com/2011/03/14/2115149/fight-is-on-to-save-drug-
monitoring.html. 
 22. Id. 
 23. SB 36, as introduced, 2011 Ga. Gen. Assem. 
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February 1, 2011.24 Lieutenant Govenor Casey Cagle (R) assigned it 
to the Health and Human Services Committee.25 
The bill, as originally introduced, provided “for the establishment 
of a program to monitor the prescribing and dispensing of Schedule 
II, III, IV, and V controlled substances.”26 The bill modified the 
definitions listed in Code section 16-13-21 by adding definitions of 
“addiction,”27 “board,”28 “patient,”29 “prescriber,”30 “Schedule II, III, 
IV, or V controlled substances,”31 and “tolerance”32 and altering the 
definitions of “bureau,”33 “dependency,”34 and “dispenser.”35 The bill 
also required dispensers to submit thirteen specific pieces of 
information regarding the dispensing of such controlled substances,36 
provided for the confidentiality of information in the database except 
for specific circumstances, and provided for penalties for misuse of 
the data.37 The bill also established an Electronic Database Review 
Advisory Committee (Advisory Committee).38 The Advisory 
Committee and other privacy protections such as the penalties for 
misuse of the data were included in the bill to address the privacy 
concerns that had prevented the bill from being passed the previous 
two years.39 
                                                                                                                                         
 24. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011. 
 25. Id. 
 26. SB 36, as introduced, p. 1, ln. 2–3, 2011 Ga. Gen. Assem. 
 27. Id. at p. 1, ln. 18–23. 
 28. Id. at p. 2, ln. 34–35. 
 29. Id. at p. 5, ln. 156–57. 
 30. Id. at p. 6, ln. 183–86. 
 31. Id. at p. 6, ln. 191–94. 
 32. SB 36, as introduced, p. 6, ln. 198–201, 2011 Ga. Gen. Assem. 
 33. Id. at p. 2, ln. 36–37 (changing the definition from “Drug Enforcement Administration, United 
States Department of Justice, or its successor agency,” to “Georgia Bureau of Investigation”). 
 34. SB 36, as introduced, p. 2–3, ln. 61–71, 2011 Ga. Gen. Assem. 
 35. Id. at p. 3, ln. 79–93. 
 36. Id. at p. 8, ln. 240–59 (including the DEA permit number or dispenser identification number, the 
date the prescription was dispensed, the prescription serial number, if the prescription is new or a refill, 
the National Drug Code for the dispensed drug, the quantity and strength dispensed, the number of days 
supply of the drug, the patient’s name, the patient’s address, the patient’s date of birth, the approved 
prescriber identification number or the prescriber’s DEA permit number, the date the prescription was 
issued by the prescriber, and “other data elements consistent with standards established by the American 
Society for Automation in Pharmacy, if designated by regulations of the board”). 
 37. Id. at p. 1, ln. 3–9. 
 38. Id. at p. 1, ln. 6–8. 
 39. Carter Interview, supra note 1. 
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The Health and Human Services Committee offered a substitute to 
SB 36.40 The substitute revised Code section 16-13-21 to define a 
“dispenser” as a person that dispenses Schedule II, III, IV, or V 
controlled substances instead of one that delivers such controlled 
substances.41 The substitute also changed Code section 16-13-21 to 
include clinics as a health care facility not covered under the 
definition of “dispenser” and expanded the type of care institutional 
pharmacies not considered “dispensers” provide from “inpatient” to 
“patient.”42 The Committee substitute also removed language in 
Code section 16-13-58 that would have allowed the State Board of 
Pharmacy (Pharmacy Board) to fund grants to dispensers to cover 
costs for dedicated equipment and software used to comply with the 
reporting requirements from “funds from the disposition of forfeited 
property.”43 
Under Code section 16-13-60, the Committee substitute modified 
to whom the Pharmacy Board will be authorized to provide 
prescription information from the database.44 The substitute allowed 
for the Pharmacy Board to provide information to officials “upon 
receipt of a subpoena issued by a court of record, located within or 
outside of this state” instead of by a “superior court in compliance 
with Georgia law and the Georgia Constitution.”45 The substitute also 
allowed for a state agency or board to receive prescription 
information only from a “subpoena issued by a superior court” 
instead of from “an administrative subpoena issued by such state 
agency, board, or entity which is authorized to receive such 
prescription information.”46 The Committee substitute also added a 
provision to Code section 16-13-60 to make clear that this bill would 
not prevent the Georgia Composite Medical Board (Medical Board) 
or other licensing board from being able to obtain patient medical 
                                                                                                                                         
 40. SB 36 (SCS), 2011 Ga. Gen. Assem. 
 41. Id. § 1, p. 3, ln. 79. 
 42. Id. § 1, p. 3, ln. 84–85. 
 43. Id. § 2, p. 7, ln. 233. 
 44. Compare Id. § 2, p. 9, ln. 308–09, with SB 36, as introduced, § 2, p. 9, ln. 306–07, 2011 Ga. 
Gen. Assem. 
 45. SB 36 (SCS), § 2, p. 9, ln. 308–09, 2011 Ga. Gen. Assem. 
 46. Compare Id. § 2, p. 9, ln. 311, with SB 36, as introduced, § 2, p. 9, ln. 308–10, 2011 Ga. Gen. 
Assem. 
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information from a practitioner solely on the basis that the 
practitioner had placed prescription information in the database.47 
The Committee substitute established a time frame for 
implementation of the database in Code section 16-13-64 by 
requiring the Pharmacy Board to certify when the database is 
established and to post a notice of the certification on the its 
website.48 Dispensers would then have 30 days to begin submitting 
prescription information to the Pharmacy Board.49 
The Health and Human Services Committee favorably reported its 
substitute on February 17, 2011, and the bill was read on the Senate 
floor for the second time on February 22, 2011.50 The bill was then 
read for the third time on February 23, 2011,51 and the Senate passed 
the Committee substitute of SB 36 by a vote of 49 to 6 on the same 
day.52 
Consideration and Passage by the House 
The bill was first introduced to the House on February 24, 2011.53 
The bill was read for the second time on February 28, 2011.54 
Speaker of the House David Ralston (R-7th) assigned it to the House 
Committee on Judiciary Non-Civil.55 
The House Committee on Judiciary Non-Civil offered a House 
Committee substitute that made several changes to the version that 
the Senate passed.56 The Committee substitute changed the definition 
of “security paper,” required that all hard copy prescriptions be on 
security paper, required identification to pick up certain prescriptions, 
and limited the units of Schedule II through IV drugs which may be 
obtained with the use of a single prescription to sixty units.57 
                                                                                                                                         
 47. SB 36 (SCS), § 2, p. 10, ln. 335, 2011 Ga. Gen. Assem. 
 48. Id. § 2, p. 11, ln. 385. 
 49. Id. § 2, p. 11, ln. 387. 
 50. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011. 
 51. Id. 
 52. Georgia State Senate Voting Record, SB 36 (Feb. 23, 2011). 
 53. Video Recording of House Proceedings, Feb. 24, 2011 at 19 min., 14 sec. (remarks by Speaker 
of the House David Ralston (R-7th), http://mediam1.gpb.org/ga/leg/2011/ga-leg-
house_022411_AM.wmv [hereinafter House First Reader Video]. 
 54. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011. 
 55. Id. 
 56. SB 36 (HCS), 2011 Ga. Gen. Assem. 
 57. Compare SB 36 (HCS), p. 1, ln. 11–16, 2011 Ga. Gen. Assem. with SB 36, as passed Senate, 
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In the House Committee on Judiciary Non-Civil hearing, 
Representative Ed Setzler (R-35th) summarized the reasons for the 
amendments.58 First, there was a concern that privacy was not being 
adequately protected.59 Also, some of the amendments were made to 
“clean up language where administrative subpoenas perhaps were a 
little looser in the bill’s language . . . than they should have been,” 
and other amendments were made to restrict the ability of other states 
to access the database.60 The subcommittee also proposed 
amendments that would have changed the drugs tracked by the 
database to Schedule II drugs along with an enumerated list as 
opposed to the original Schedule II, III, IV, and V drugs.61 These 
amendments were later overridden by a Committee hearing 
amendment which, limited coverage to Schedule II, III, IV, and V 
drugs.62 
The subcommittee also introduced an amendment to change the 
requirements of any entity that has access to the database to have 
“security measures that are substantially equivalent” to those of the 
Pharmacy Board.63 This was meant to provide more security than the 
Senate bill’s requirement that the entity “maintain security 
procedures consistent with the size and sophistication of the 
organization.”64 Representative Setzler (R-35th) recognized that, “as 
a powerful thing, [this bill] has to be adequately shackled.”65 
The substitute as recommended by the House Committee on 
Judiciary Non-Civil made several other changes to the bill passed by 
the Senate. It added a definition of “agency” to the definitions in 
Code section 16-13-21 and defined it to mean the Georgia Drugs and 
Narcotics Agency.66 The Committee substitute also amended Code 
section 16-13-59 to refer to the “agency” instead of the “board,” thus 
                                                                                                                                         
p.1, ln. 1–10, 2011 Ga. Gen. Assem. 
 58. House Committee Video, supra note 5 at 14 min., 48 sec. (remarks by Rep. Ed Setzler (R-35th)). 
 59. Id. 
 60. Id. 
 61. House Committee Video, supra note 5, at 18 min., 58 sec. (remarks by Rep. Ed Setzler (R-
35th)). 
 62. Id. at 52 min., 28 sec. (remarks by Rep. Edward Lindsey (R-54th)) (Rep. Lindsey offering his 
amendment). 
 63. Id. at 18 min., 58 sec. (remarks by Rep. Ed Setzler (R-35th)). 
 64. Id. 
 65. Id. 
 66. SB 36 (HCS), § 1, p. 2, ln. 37, 2011 Ga. Gen. Assem. 
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requiring dispensers to send information regarding each prescription 
filled to the Georgia Drugs and Narcotics Agency (Agency) instead 
of the Board.67 The Committee substitute also changed the definition 
of a “dispenser” to one that delivers a drug instead of one that 
dispenses, going back to the definition in the bill as originally 
introduced.68 Also in the definitions section, “veterinarian” was 
removed from the definition of a “practitioner.”69 To further prevent 
other states and the federal government from accessing the database, 
the Committee extended the reach of new Code section 16-13-58(a) 
to prohibit “the board, agency, [or] any other state entity” from 
accepting “a grant that requires as a condition of the grant any 
sharing of information that is inconsistent with this part.”70 The 
Committee also modified Code section 16-13-58 by adding back in 
the ability for the Agency to provide funds from the disposition of 
forfeited property to dispensers for covering the costs of equipment 
and software.71 The Committee also added in two more pieces of 
information dispensers would need to submit to the Agency for each 
prescription purchase—the gender of the patient and the method of 
payment.72 
To further protect the privacy of the data, the Committee changed 
the amount of time that the Agency could keep the identifying 
prescription information in the electronic database from two years to 
one year.73 The Committee expanded the coverage of the bill by 
adding in Code section 16-13-59(g), which would require 
wholesalers to provide the Agency with the amounts of Schedule II, 
III, IV, and V controlled substances that it ships to each dispenser in 
the state.74 However, the Committee also added Code section 16-13-
65(b), which made clear that this bill would not cover over-the-
counter Schedule V controlled substances.75 The Committee 
substitute also limited those with whom the Agency could provide 
                                                                                                                                         
 67. Id. § 2, p. 9, ln. 278–309. 
 68. Id. § 1, p. 3, ln. 88. 
 69. Id. § 1, p. 6, ln. 176. 
 70. Id. § 2, p. 7–8, ln. 239–44. 
 71. Id. § 2, p. 8, ln. 248–49. 
 72. SB 36 (HCS), § 2, p. 8, ln. 272–73, 2011 Ga. Gen. Assem. 
 73. Id. § 2, p. 9, ln. 296–300. 
 74. Id. § 2, p. 9, ln. 305–09. 
 75. Id. § 2, p. 13, ln. 432–34. 
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information from the database. Besides dispensers, patients, and 
prescribers, the Agency would be allowed to provide database 
information to local, state, or federal law enforcement pursuant to a 
search warrant and to the Agency or Medical Board upon the 
issuance of an administrative subpoena issued by a Georgia state 
administrative law judge.76 Further protecting the privacy of Georgia 
prescription drug purchasers, the bill also removed the provision in 
the Senate’s version of the bill that would allow the Pharmacy Board 
to prepare a plan to share database information with other states.77 
One concern of the bill’s sponsor, Senator Buddy Carter (R-1st), 
was to make sure the patients that truly need medication can still get 
it.78 To address this concern, the Committee amended the bill to 
expand Code section 16-13-62 to make clear that nothing in the bill 
should “impede, impair, or limit a prescriber from prescribing pain 
medication in accordance with the pain management guidelines 
developed and adopted by the Georgia Composite Medical Board.”79 
Other changes included removing the requirement of posting the 
certification of the database on the Pharmacy Board’s website and the 
requirement that dispensers begin to submit prescription information 
within thirty days of such posting.80 
To protect the privacy of Georgia residents’ data, the Committee 
substitute provided even harsher penalties for abuse of the database 
and the information contained within.81 Additionally, amendments to 
Code section 16-13-64 increased the punishment for a dispenser 
knowingly and intentionally failing to submit prescription 
information to the database from a misdemeanor to a felony and 
increased the possible prison time to not less than one year and the 
fine limit to $50,000.82 The substitute extended prison time to at least 
one year for database breaches by both persons authorized to access 
                                                                                                                                         
 76. Id. § 2, p. 10, ln. 329–32. 
 77. Compare SB 36, as passed Senate, § 2, p. 10, ln. 319–22, 2011 Ga. Gen. Assem., with SB 36 
(HCS), § 2, p. 13, ln. 333–40, 2011 Ga. Gen. Assem. (removing O.C.G.A. § 11-12-13(e)). 
 78. House Committee Video, supra note 5, at 26 min., 06 sec. (remarks by Sen. Buddy Carter (R-
1st)). 
 79. SB 36 (HCS), § 2, p. 12, ln. 385–87, 2011 Ga. Gen. Assembly. 
 80. Compare SB 36, as passed Senate, § 2, p. 12–13, ln. 385–388, 2011 Ga. Gen. Assem., with SB 
36 (HCS), § 2, p. 12, ln. 396–402, 2011 Ga. Gen. Assem. (removing proposed O.C.G.A. § 16-13-64(a)). 
 81. House Committee Video, supra note 5, at 12 min., 55 sec. (remarks by Sen. Buddy Carter (R-
1st)). 
 82. SB 36 (HCS), § 2, p. 12, ln. 396–402, 2011 Ga. Gen. Assem. 
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the database and anyone who obtains, attempts to obtain, or discloses 
database information under false pretenses.83 Anyone who would use 
the information in the database for commercial advantage, personal 
gain, or malicious harm would be punished by a prison term of not 
less than two years.84 
To further reign in the influx of drug seekers from other states and 
the rise of pill mills in Georgia, the Committee substitute made 
changes to how prescriptions are written. First, it added sections 3, 4, 
and 5, which defined what security paper could be used for 
prescriptions85 and would require all hard copy prescriptions to be 
written on security paper.86 Second, the Committee substitute added 
Code section 26-4-80.2, which prevents pharmacists from filling 
prescriptions for more than sixty units of any drug in Schedules II, 
III, or IV.87 
With these changes, the House Committee on Judiciary Non-Civil 
favorably reported the Committee substitute on March 28, 2011.88 
The bill was postponed on March 30, 2011, but then read for the third 
time and debated on March 31, 2011.89 Despite concerns about 
privacy and funding voiced by opponents of the bill during the House 
floor debate, the bill passed the House by a vote of 117 to 45 on 
March 31, 2011.90 The bill was then sent back to the Senate to 
resolve the differences between the House and Senate versions of the 
bill.91 
                                                                                                                                         
 83. Id. § 2, p. 12, ln. 410–18. 
 84. Id. § 2, p. 13, ln. 419–23. 
 85. Id. § 2, p. 13, ln. 439–55 (defining “security paper” as “a prescription pad or paper that has been 
approved by the board for use and contains the following characteristics: (A) One or more industry 
recognized features designed to prevent unauthorized copying of a completed or blank prescription 
form; (B) One or more industry recognized features designed to prevent the erasure or modification of 
information written on the prescription form by the practitioner; and (C) One or more industry 
recognized features designed to prevent the use of counterfeit prescription forms”). 
 86. Id. § 2–5. 
 87. Id. § 5, p. 15, ln. 502–05. 
 88. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011. 
 89. Id. 
 90. Georgia House of Representatives Voting Record, SB 36 (Mar. 31, 2011). 
 91. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011. 
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Senate Amendment 
The Senate took up the changes made by the House on April 14, 
2011.92 Senator Carter offered a floor amendment to the House 
Committee substitute.93 The amendment removed the definition of 
“Wholesalers”94 and the wholesalers’ requirement to report the 
quantity of Schedule II, III, IV, and V controlled substances shipped 
to dispensers from the House version of the bill.95 The amendment 
added the consumer member that the Governor appoints to the 
Pharmacy Board pursuant to Code section 26-4-21 as the tenth 
member to the Advisory Committee.96 The amendment also removed 
the requirement that pharmacists copy the identification document of 
persons picking up prescriptions for other people.97 Senator Carter’s 
amendment also limited the requirement for security paper for 
prescriptions to Schedule II controlled substances.98 The amendment 
also removed the sixty unit limit on prescriptions pharmacists filling 
Schedule II through IV controlled substances.99 
The Senate agreed with the House Committee substitute as 
amended by the Senate by a vote of 53–3, and the House agreed to 
Senate’s changes 131–32 on April 14, 2011.100 The Senate then sent 
the bill to the Governor on April 19, 2011.101 Governor Nathan Deal 
signed the bill into law on May 13, 2011.102  
The Act 
The Act amends Title 16 of the Official Code of Georgia 
Annotated with the purpose of reducing the abuse of controlled 
                                                                                                                                         
 92. Id. 
 93. SB 36 (SFA), 2011 Ga. Gen. Assem. 
 94. Id. at p. 1, ln. 8. 
 95. Id. at p. 1, ln. 9. 
 96. Id. at p. 1, ln. 17–23. 
 97. Id. at p. 1–2, ln. 24–27. 
 98. Id. at p. 2, ln. 28–29. 
 99. SB 36 (SFA), p. 2, ln. 31, 2011 Ga. Gen. Assem. 
 100. Georgia Senate Voting Record, SB 36 (Apr. 14, 2011); Georgia House of Representatives 
Voting Record, SB 36 (Apr. 14, 2011); State of Georgia Final Composite Status Sheet, SB 36, May 24, 
2011. 
 101. Id. 
 102. Office of the Governor, May 13, 2011: Bills Signed by Governor Deal, 
http://gov.georgia.gov/00/article/0,2086,165937316_170511855_171299722,00.html. 
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substances and thereby improving the quality of healthcare. The Act 
defines numerous terms by amending Code section 16-13-21.103 This 
section adds definitions of “addiction,” “patient,” “prescriber,” 
“schedule II, III, IV, or V controlled substance,” and “tolerance.”104 
It also defines “agency” as the Georgia Drugs and Narcotics Agency, 
“board” as the State Board of Pharmacy, and amends “bureau” to 
mean the Georgia Bureau of Investigation.105 This section amends the 
definition of “dependent” and “dispenser.”106 “Dispenser” was 
amended to exclude hospital pharmacies, institutional pharmacies, 
direct administration of the controlled substance, and prison 
pharmacies.107 
Section 2 of the Act establishes the prescription monitoring 
database, provides for its security, and sets out the penalties for 
breaching such security.108 First, it amends the chapter by adding Part 
2 and designating Article 2 as Part 1 of Article 2.109 It adds Code 
section 16-13-57, which requires the Agency to establish and 
maintain “a program to electronically record into an electronic 
database prescription information” related to Schedule II, III, IV, or 
V controlled substances subject to funding either by the State or as 
otherwise available.110 This section also clarifies that the purpose of 
the Act is to reduce the abuse of controlled substances and to 
improve quality of care by promoting appropriate prescribing 
practices.111 It authorizes the Agency to administer the program at the 
direction and oversight of the Pharmacy Board.112 
                                                                                                                                         
 103. O.C.G.A. § 16-13-21 (Supp. 2011). 
 104. Id. 
 105. “Bureau” was amended from the Drug Enforcement Administration, United States Department 
of Justice. Compare O.C.G.A. § 16-13-21 (Supp. 2010) with O.C.G.A. § 16-13-21 (Supp. 2011). 
 106. O.C.G.A. § 16-13-21 (Supp. 2011). 
 107. An “institutional pharmacy” includes a nursing home, intermediate care home, personal care 
home, or a hospice program, which provides care and administers the controlled substance “on the 
premises of the facility.” O.C.G.A. § 16-13-21(10)(B) (Supp. 2011). “Administer” means the “direct 
application of a controlled substance.” O.C.G.A. § 16-13-21(1) (Supp. 2011). 
 108. O.C.G.A. § 16-13-57 to -65. 
 109. Id. 
 110. The General Assembly did not appropriate the $400,000–$1.2 million to the Georgia Drugs and 
Narcotics Agency to establish the database in the budget. Hunt, supra note 1. However, the section 
allows the agency to seek other sources, such as federal or private funds. O.C.G.A. § 16-13-57(a) (Supp. 
2011). See also supra text accompanying notes 15–18 and infra text accompanying notes 174–88. 
 111. Appropriate prescribing practices include “proper use of medications to treat pain and terminal 
illness,” overprescribing, and duplicative prescribing. O.C.G.A. § 16-13-57(a) (Supp. 2011). 
 112. O.C.G.A. § 16-13-57(b) (Supp. 2011). 
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Section 2 also adds Code section 16-13-58, which authorizes the 
Agency to apply for funding and accept gifts in order to develop and 
maintain the prescription monitoring database, so long as the 
conditions of the funding do not require information sharing that is 
inconsistent with this part.113 Code section 16-13-58 also grants the 
Agency authority to provide funds to individual dispensers for the 
purpose of compliance with this section.114 This section also makes 
clear that no appropriation of state funds is required.115 
The Act adds Code section 16-13-59, which establishes the 
information that each dispenser must submit to the Agency for any 
Schedule II, III, IV, or V controlled substance.116 The required 
information includes at a minimum: Drug Enforcement Agency 
(DEA) permit or dispenser facility controlled substance identification 
number, date the prescription was dispensed, prescription serial 
number, if the prescription is new or a refill, National Drug Code for 
drug dispensed, quantity and strength dispensed, number of days 
supply of the drug, patient’s name, address, date of birth, gender, 
method of payment, date the prescription was issued by the 
prescriber, and other data consistent with standards established by the 
American Society for Automation in Pharmacy.117 Dispensers are 
required to submit the required prescription information on at least a 
weekly basis and at a minimum no later than ten days after the 
prescription is dispensed.118 This Code section also requires that 
dispensers that are temporarily unable to comply with the submission 
rules notify the Pharmacy Board and the Agency.119 Additionally, the 
Agency may issue a waiver to any dispenser that is unable to comply 
with the reporting requirements.120 Code section 16-13-59 prohibits 
the Agency from revising the required information more frequently 
than annually and any such changes are effective and applicable to 
                                                                                                                                         
 113. O.C.G.A. § 16-13-58 (Supp. 2011). 
 114. It is likely that this clause was required for passage due to limited funds in the budget. O.C.G.A. 
§ 16-13-58(b) (Supp. 2011). 
 115. O.C.G.A. § 16-13-58(c) (Supp. 2011). 
 116. O.C.G.A. § 16-13-59(a) (Supp. 2011). 
 117. O.C.G.A. § 16-13-59(a)(1)-(15) (Supp. 2011). 
 118. O.C.G.A. § 16-13-59(b) (Supp. 2011). 
 119. Id. 
 120. The waiver request must be in writing when submitted to the agency. The waiver may permit a 
dispenser to submit the required prescription information by paper form or other means, so long as all of 
the required information is included. O.C.G.A. § 16-13-59(c) (Supp. 2011). 
15
: Crimes and Offenses SB 36
Published by Reading Room, 2011
284 GEORGIA STATE UNIVERSITY LAW REVIEW [Vol. 28:1 
 
dispensers six months after they are adopted.121 The Agency is 
prohibited from accessing or allowing access to any identifying 
prescription information in the electronic database after one year 
from its inclusion in the database.122 Additionally, the Agency is 
required to promulgate rules and procedures that will “ensure that 
any identifying information the agency receives from any dispenser 
or reporting entity that is one year old or older is deleted or destroyed 
on an ongoing basis in a timely and secure manner.”123 
Section 2 of the Act adds Code section 16-13-60, which first 
establishes that the prescription information submitted pursuant to 
Code section 16-13-59 is confidential and exempt from open records 
requirements.124 It further requires that the Agency and the Pharmacy 
Board “establish and maintain strict procedures to ensure that the 
privacy and confidentiality of patients, prescribers, and patient and 
prescriber information collected, recorded, transmitted, and 
maintained pursuant to this part are protected.”125 The permitted 
disclosures are limited to: (1) authorized prescribers or dispensers of 
controlled substances for the purpose of providing care to a specific 
patient, (2) upon request by a patient, prescriber or dispenser where 
the information concerns the requestor, (3) to local, state, or federal 
law enforcement or prosecutorial officials pursuant to a search 
warrant, and (4) to the Medical Board pursuant to an administrative 
subpoena.126 It prohibits disclosure to any person or entity not 
specified and only in accordance with HIPAA standards.127 
Code section 16-13-60 allows the disclosure of de-identified 
prescription information to governmental entities for statistical 
research, educational, or grant application purposes.128 It also 
                                                                                                                                         
 121. O.C.G.A. § 16-13-59(d) (Supp. 2011). 
 122. O.C.G.A. § 16-13-59(e) (Supp. 2011). 
 123. Id. 
 124. O.C.G.A. § 16-13-60(a) (Supp. 2011); Open records laws allow interested individuals, firms, 
corporations, or other entities to inspect, extract, or make copies of any public record. O.C.G.A. § 50-
18-70. 
 125. O.C.G.A. § 16-13-60(b) (Supp. 2011). 
 126. O.C.G.A. § 16-13-60(c) (Supp. 2011). 
 127. O.C.G.A. § 16-13-60(b) (Supp. 2011). The Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 prohibits disclosure of protected health information except under limited 
circumstances. 42 U.S.C.A. § 102 (1996). 
 128. The disclosed prescription information must be stripped of information that “could be used to 
identify prescribers or individual patients or persons who received prescriptions from dispensers. 
O.C.G.A. § 16-13-60(d) (Supp. 2011). 
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prohibits any person or entity permitted to receive prescription 
information from subsequently providing that information to any 
other person or entity unless required by court order.129 This section 
requires any permissible user who directly accesses the prescription 
information contained in the database to implement and maintain a 
“comprehensive information security program” that includes security 
measures equal to those of the Agency.130 Finally, the Act does not 
modify, limit, diminish, or impliedly repeal any authority of a 
licensing or regulatory board, or other entity authorized to obtain 
prescription information from other sources, provided that the 
Agency may release information only in accordance with this 
section.131 
Code section 16-13-61 creates an Electronic Database Review 
Advisory Committee (Advisory Committee) to consult with and 
advise the Agency on the establishment, maintenance, and operation 
of the electronic prescription database.132 The Advisory Committee 
will consist of ten uncompensated members each serving a three-year 
term, with five members constituting a quorum.133 It will meet at 
least once per year or by request of the chairperson or at least three 
members.134 
Section 2 adds Code section 16-13-62, which requires the Agency 
to establish rules and regulations in order to implement the Act.135 
Simultaneously, it prohibits the Agency from establishing policies, 
rules, or regulations that limit, revise, or expand the prescription or 
                                                                                                                                         
 129. O.C.G.A. § 16-13-60(e) (Supp. 2011). 
 130. The comprehensive information security program must include administrative, technical, and 
physical safeguards and the user must identify “foreseeable internal and external risks to the security, 
confidentiality, and integrity of the personal information that could result in the unauthorized disclosure, 
misuse, or other compromise of the information.” O.C.G.A. § 16-13-60(f) (Supp. 2011). 
 131. O.C.G.A. § 16-13-60(g) (Supp. 2011). 
 132. The committee will: review methods of data collection, access, and security, evaluate data to 
“identify benefits and outcomes of the reviews,” and communicate with prescribers and dispensers about 
the reviews and database use. O.C.G.A. § 16-13-61(a) (Supp. 2011). 
 133. The committee must include one representative each, from the Georgia Drugs and Narcotics 
Agency, the Georgia Composite Board of Medicine, the Georgia Board of Dentistry, and the Georgia 
Board of Optometry. It must also include an expert in personal privacy matters appointed by the State 
Bar of Georgia and an addiction professional, a pain management specialist, an oncologist, and a 
hospice representative, each appointed by the Georgia Composite Medical Board. The tenth member of 
the committee must be a consumer member appointed by the Governor to the State Board of Pharmacy 
under Code section 26-4-21. O.C.G.A. § 16-13-61 (Supp. 2011). 
 134. O.C.G.A. § 16-13-61 (Supp. 2011). 
 135. O.C.G.A. § 16-13-62 (Supp. 2011). 
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dispensing authority of any prescribers or dispensers subject to this 
part, including the authority to prescribe pain medication in 
accordance with the Medical Board’s pain management guidelines.136 
Code section 16-13-63 was added to limit the liability of a 
prescriber or dispenser, stating that they have no duty to obtain 
prescription information about a patient and shall not be held civilly 
liable or criminally responsible for damages or injury based on a 
failure to obtain prescription information from the database.137 
Section 2 adds Code section 16-13-64, which sets out penalties for 
failure to submit prescription information to the database and 
improper disclosure of information contained in the database.138 First, 
a dispenser who knowingly and intentionally fails to submit or 
submits incorrect prescription information is guilty of a felony and 
faces not less than one year nor more than five years imprisonment 
and a fine not to exceed $50,000 for each offense.139 Additionally, 
the offense is reported to the dispenser’s licensing board.140 Second, 
an individual permitted to access prescription information contained 
in the database who negligently uses, releases, or discloses 
information in violation of this part is guilty of a misdemeanor for the 
first offense and a felony for the second offense, subject to 
imprisonment for not less than one year and not more than three 
years and a fine not to exceed $5,000.141 Third, an individual 
permitted to access prescription information contained in the 
database who knowingly obtains or discloses information in violation 
of this part is guilty of a felony and faces punishment of not less than 
one year but not more than five years imprisonment and a $50,000 
fine.142 
Under new Code section 16-13-64, any person who knowingly 
obtains or discloses prescription information under false pretenses is 
guilty of a felony, punishable by imprisonment for not less than one 
year and not more than five years and a fine of $100,000.143 Any 
                                                                                                                                         
 136. Id. 
 137. O.C.G.A. § 16-13-63 (Supp. 2011). 
 138. O.C.G.A. § 16-13-64 (Supp. 2011). 
 139. O.C.G.A. § 16-13-64(a) (Supp. 2011). 
 140. Id. 
 141. O.C.G.A. § 16-13-64(b) (Supp. 2011). 
 142. O.C.G.A. § 16-13-64(c)(1) (Supp. 2011). 
 143. O.C.G.A. § 16-13-64(c)(2) (Supp. 2011). 
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unauthorized person who obtains or discloses prescription 
information with the intent to sell, transfer, or use the information for 
commercial or personal gain or malicious harm is guilty of a felony 
and faces not less than two years and not more than ten years 
imprisonment and a fine not to exceed $250,000.144 This section 
continues to provide a cause of action for actual damages, punitive 
damages where appropriate, attorney fees, and litigation expenses to 
any person injured by reason of a violation of this part.145 All 
penalties in Code section 16-13-64 are intended to be cumulative of 
other applicable penalties and and this section does not repeal 
alternative penalties.146 
New Code section 16-13-65 exempts veterinarians from the 
provisions of this part and makes this part inapplicable to “any drug, 
substance, or immediate precursor classified as an exempt over-the-
counter Schedule V controlled substance pursuant to this chapter or 
pursuant to Pharmacy Board rules established in accordance with 
Code section 16-13-29.2.”147 
Section 3 of the Act amends Chapter 4 of Title 26 of the Official 
Code of Georgia Annotated by revising paragraph (38.5) of Code 
section 26-4-5, redefining “security paper” to mean an approved 
prescription pad or paper that contains industry recognized features 
designed to prevent unauthorized copying, erasure or modification of 
information written on the paper, and counterfeit use.148 It also 
requires that any pad of security paper bears an identifying lot 
number and that each page is numbered sequentially beginning with 
the number one.149 
Section 4 further amends Code section 26-4-80 by requiring any 
person picking up a Schedule II controlled substance to present photo 
identification that displays the person’s full name.150 
                                                                                                                                         
 144. O.C.G.A. § 16-13-64(c)(3) (Supp. 2011). 
 145. O.C.G.A. § 16-13-64(d) (Supp. 2011). 
 146. O.C.G.A. § 16-13-64(e) (Supp. 2011). 
 147. O.C.G.A. § 16-13-65 (Supp. 2011). Code section 16-13-29.2 grants the Board of Pharmacy 
authority to exempt and control the sale of Schedule V controlled substances without requiring a 
prescription. O.C.G.A. § 16-13-29.2 (2010). 
 148. O.C.G.A. § 26-4-5(38.5) (Supp. 2011). 
 149. Id. 
 150. O.C.G.A. § 26-4-80(1) (Supp. 2011). 
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Section 5 of the Act adds Code section 26-4-80.1, which requires 
that every hard copy prescription for any Schedule II controlled 
substance be written on security paper.151 It prohibits a pharmacist 
from filling a hard copy prescription for any Schedule II controlled 
substance unless it is on security paper. This rule does not apply in an 
emergency, however.152 The section requires that a hard copy of an 
electronic Schedule II controlled substance prescription drug order 
given directly to the patient be manually signed and on security paper 
approved under Code section 26-4-5.153 Prescribers must implement 
proper safeguards to prevent theft or unauthorized use of security 
paper and report any theft or unauthorized use to appropriate 
authorities.154 This section also requires vendors to get approval by 
the Pharmacy Board for their security paper prior to sale or 
marketing in Georgia.155 The Pharmacy Board also must create a seal 
of approval confirming that security paper contains the required 
industry recognized characteristics listed in paragraph (38.5) of Code 
section 26-4-5 and the seal must be affixed to all security paper used 
in Georgia.156 The Pharmacy Board is permitted to adopt rules 
necessary to administer this Code section.157 Finally, this Code 
section does not apply to prescriptions transmitted to the pharmacy 
through facsimile, telephone, or electronic means, nor for 
prescriptions written for hospital inpatients or outpatients, nursing 
home residents, mental health facility inpatients or residents, or 
prisoners incarcerated in a local, state, or federal correctional facility, 
when the prescription is written into the patient’s medical record, the 
order is given to the pharmacy directly, and the patient has no 
opportunity to handle the written order.158 
                                                                                                                                         
 151. This provision is effective October 11, 2011. O.C.G.A. § 26-4-80.1(a) (Supp. 2011). 
 152. O.C.G.A. § 26-4-80.1(b) (Supp. 2011). 
 153. O.C.G.A. § 26-4-80.1(c) (Supp. 2011). 
 154. O.C.G.A. § 26-4-80.1(d) (Supp. 2011). 
 155. O.C.G.A. § 26-4-80.1(e) (Supp. 2011). 
 156. O.C.G.A. § 26-4-80.1(f) (Supp. 2011). 
 157. O.C.G.A. § 26-4-80.1(g) (Supp. 2011). 
 158. O.C.G.A. § 26-4-80.1(h) (Supp. 2011). 
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Analysis 
Two significant areas of contention during the drafting of the Act 
were privacy and funding.159 The two issues are intertwined, as the 
Act’s strict privacy protections were necessary to ensure its passage, 
yet may preclude available federal funding grants. Because the 
General Assembly did not allocate the funds needed to create the 
database, outside sources are the only available means to fund the 
project.160 The Act, however, may not meet federal grant 
requirements due to the privacy restrictions, so limited funding 
options are available and may ultimately prevent creation of the 
database.161 
Privacy 
Privacy remains an issue for the Act going forward, despite 
proponents’ efforts to address the concerns during the legislative 
process.162 The Act aims to protect privacy in three ways: regulating 
who can access the data; creating an Advisory Committee to manage 
the database’s security; and providing substantial penalties for 
violating the access protocols of the database information. 
First, the Act limits who has access to the data.163 It permits 
disclosure of patient prescription information only to authorized 
prescribers or dispensers for providing care to a specific patient, upon 
request by a patient, prescriber, or dispenser about whom the 
information concerns, to law enforcement with a search warrant, or to 
the Agency or Medical Board with an administrative subpoena.164 
The Act does not permit sharing of patient prescription information 
with other states or the Federal government except with a 
subpoena.165 Although passage of the Act was contingent on the 
                                                                                                                                         
 159. See Carter Interview supra note 1. 
 160. See Hunt, supra note 1. 
 161. Id. 
 162. See Carter Interview supra note 1; House Committee Video, supra note 5, at 14 min., 48 sec. 
(remarks by Rep. Ed Setzler (R-35th)). 
 163. O.C.G.A. § 16-13-60(c) (Supp. 2011). 
 164. Id. 
 165. Hunt, supra note 1. 
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inclusion of these strict privacy provisions, the provisions also limit 
available sources of funding.166 
The second privacy concern raised during the development of the 
Act was that of security breaches that might reveal database 
information to unauthorized third parties.167 As Representative 
Christian Coomer (R-14th) noted, the Act “creates a very target-rich 
environment for bad actors to try to go and steal that information.”168 
Representative Coomer also cited recent data breaches of the Sony 
Corporation’s PlayStation user database that revealed 70 million 
users’ sensitive data.169 Proponents of the Act noted such security 
concerns,170 and through the addition of Code section 16-13-61, the 
Act establishes an Advisory Committee that would monitor security 
and access of the database.171 Until the Advisory Committee’s 
regulations are in place, there is no way to determine whether the 
security placed on the database by the Advisory Committee’s 
regulations will be more effective than those of Sony’s breached 
database. 
To further address security and privacy concerns, proponents of 
the Act added substantial penalties for those guilty of unauthorized 
access to the database or unauthorized dissemination of database 
information.172 Classifying violations as felonies with punishments 
up to $250,000 in fines and up to ten years in prison should serve to 
deter security breaches.173 
Funding 
Although the Act establishes a prescription monitoring database, 
its creation, implementation, and maintenance will require a 
                                                                                                                                         
 166. Id; see also text accompanying notes 174–88. 
 167. House First Reader Video, supra note 53 at 1 hr., 52 min., 47 sec. (remarks by Rep. Christian 
Coomer (R-14th)), http://mediam1.gpb.org/ga/leg/2011/ga-leg-house_033111_PM2.wmv. 
 168. Telephone Interview with Rep. Christian Coomer (R-14th) (May 11, 2011) [hereinafter Coomer 
Interview] (on file with the Georgia State University Law Review). 
 169. Id. 
 170. House Committee Video, supra note 5, at 14 min., 48 sec. (remarks by Rep. Ed Setzler (R-
35th)). 
 171. O.C.G.A. § 16-13-61 (Supp. 2011). 
 172. House Committee Video, supra note 5, at 13 min., 00 sec. (remarks by Sen. Buddy Carter (R-
1st)). 
 173. O.C.G.A. § 16-13-64 (Supp. 2011). 
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significant amount of money.174 Since the legislature did not provide 
state funding for the database, the Agency will have to look to federal 
or private funding to implement it.175 Federal funding is available 
through the National All Schedules Prescription Electronic Reporting 
Act of 2005 (NASPER) so long as the state law meets the federal 
requirements.176 In order to receive funding through NASPER, a state 
prescription monitoring database must require reporting of all 
Schedule II, III, and IV controlled substances.177 The Act fulfills this 
requirement by including all Schedule II, III, IV, and V controlled 
substances.178 
One goal of NASPER funding is to incentivize states to share 
information with each other because it is common for addicts or drug 
dealers to cross state lines to fill prescriptions.179 If neighboring 
states do not share information with each other, law enforcement is 
unable to stop this practice. However, as Representative Coomer 
pointed out, if the Pharmacy Board receives federal funding from a 
grant established by NASPER, part of the requirement of doing so is 
opening the database up to all other states that have similar programs 
in place.180 Because the Act prohibits disclosure to any unauthorized 
entity, which includes neighboring states without a search warrant, it 
is unlikely that Georgia’s prescription monitoring program will 
qualify for the grant.181 Furthermore, the Act prevents the Pharmacy 
Board, Agency, and any state entity from accepting a grant to fund 
the database “that requires as a condition of the grant any sharing of 
information that is inconsistent with this part.”182 Even if Georgia 
does qualify for federal aid, the deadline for 2011 grant applications 
                                                                                                                                         
 174. Estimates range from $400,000 to $1.2 million. Hunt, supra note 1. 
 175. Id. 
 176. National All Schedules Prescription Electronic Reporting Act of 2005, Pub. L. No. 109-60, 119 
Stat. 1979 (2005); See also Prescription Drug Monitoring Expands, 38 No.1 Controlled Substance 
Handbook Newsletter 4, July, 2009. 
 177. See Prescription Drug Monitoring Expands, supra note 176. 
 178. O.C.G.A. § 16-13-57(a) (Supp. 2011). 
 179. See Nasper Funding Assists States’ Prescription Monitoring Programs, 38 NAT’L ASS’N OF BDS. 
OF PHARMACY NEWSL., Aug. 2009; Prescription Drug Monitoring Expands, supra note 176. 
 180. Coomer Interview, supra note 168. 
 181. Hunt, supra note 1. 
 182. O.C.G.A. § 16-13-58(a) (Supp. 2011). 
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has passed.183 Nevertheless, the Agency is moving ahead with its 
application for the federal money.184 
Private funding may also be available.185 In fact, the drug company 
that manufactures Oxycontin offered $1 million to fund Florida’s 
prescription monitoring database.186 Pharmaceutical companies have 
an incentive to aid states in setting up prescription drug monitoring 
programs.187 These companies seek to keep their products on the 
shelves so that patients in need have access to them.188 
Currently, it is unclear when or if Georgia’s prescription drug 
monitoring program will be up and running. If the Agency is 
successful in obtaining funding, the program may be operational by 
2013.189 If not, the program may just be a great idea that never comes 
to life. 
Jared Bruff & Megan Daugherty 
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